• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

    4.390 +0.070 (+1.62%)
    Streaming Delayed Price Updated: 10:41 AM EDT, May 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 472,766
    Open 4.300
    Bid (Size) 4.390 (200)
    Ask (Size) 4.400 (3,800)
    Prev. Close 4.320
    Today's Range 4.300 - 4.435
    52wk Range 2.120 - 7.550
    Shares Outstanding 38,886,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire

    Performance

    YTD
    -31.9%
    -31.9%
    1 Month
    +7.6%
    +7.6%
    3 Month
    +11.4%
    +11.4%
    6 Month
    -21.3%
    -21.3%
    1 Year
    +54.0%
    +54.0%

    More News

    Read More
    News headline image
    AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    AQUESTIVE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    AQUESTIVE DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
    From Robbins LLP
    Via Business Wire
    News headline image
    ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
    Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
    What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
    The current price of Aquestive Therapeutics, Inc. - Common Stock is 4.390
    When was Aquestive Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 05/11/26 10:41 AM ET
    What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
    The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 170.72M
    How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
    Aquestive Therapeutics, Inc. - Common Stock has 171M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.